CureFAKtor recently received Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for CFAK-C4 in combination with gemcitabine for the treatment of pancreatic cancer, a disease with the lowest survival rate of any cancer and limited patient treatment options, and is planning a Phase I clinical study in 2012.
"Focal Adhesion Kinase protein binding inhibitors, such as CFAK-C4, represent a promising area of research as FAK is expressed at extremely high levels in solid cancer tumors and serves as a survival mechanism by signaling tumor growth, invasion and metastasis," said H. Shep Wild. "We have strong ties to the University of Florida Shands Cancer Center and we look forward to progressing this important research in order to help cancer patients."
CureFAKtor CFAK-C4 Research Results
CureFAKtor recently presented preclinical research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.
In a poster presentation, CureFAKtor reported that the study pinpointed the site of interaction of VEGFR-3 and FAK to create small molecule drugs capable of disrupting signaling and causing death of pancreatic cancer cells. CureFAKtor's lead compound, CFAK-C4, reduced tumor growth in vivo in mouse pancreatic cancer cells by up to 60 percent, and CFAK-C4 combined with chemotherapy drug gemcitabine had a synergistic effect and led to 80 percent pancreatic cancer tumor reduction.
The study also found that CFAK-C4 combined with gemcitabine had a prolonged effect on pancreatic tumor growth. Two weeks after treatment, the tumor size in the previously treated group was approximately 75 percent smaller than
|SOURCE CureFAKtor Pharmaceuticals, LLC|
Copyright©2010 PR Newswire.
All rights reserved